Aclarion

ACON

Market cap $4.68M

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U.

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20 th at 12:00 pm PT at the LD Micro Main Event BROOMFIELD, Colo.

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D.

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo.

Presentation on Monday, October 20, 2025 at 12:00 PM PT Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the 19th Annual Main Event on Monday, October 20, 2025 at 12:00 PM PT at the Hotel del Coronado in San Diego, CA. Jeff Thramann, Executive Chairman and Brent Ness, Chief Executive Officer will be giving the presentation.

Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challenges BROOMFIELD, Colo., October 7, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

BROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star - Clinical Diagnostic Device category for the prestigious 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH.

BROOMFIELD, Colo., October 1, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe '25 which is now available to investors and stakeholders.

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity BROOMFIELD, Colo., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced the appointment of Greg Gould as Chief Financial Officer (CFO), effective immediately.